SCHEMBL3073403

SCHEMBL3073403

COC(=O)Cn1c(-c2ccc(Cl)cc2C=O)c(C2CCCCC2)c2ccc(C(=O)OC)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP14 P54578 1/20 0.39
PTGDR Q13258 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
CNR2 P34972 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ATM Q13315 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP3A4 P08684 5/20 0.37
CYP2C19 P33261 5/20 0.37
CYP2C9 P11712 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
SCN9A Q15858 3/20 0.36
PLA2G1B P04054 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093138 0.84 PRKCA (0.37) USP14PTGDRPTGDR2ALDH1A1NPSR1
SCHEMBL3095427 0.83 PRKCA (0.38) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL3088640 0.81 PRKCA (0.40) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL10293514 0.81 ALDH1A1 (0.38) USP14CNR2ALDH1A1NPSR1ATM
SCHEMBL2277343 0.80 KCNH2 (0.40) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL10293456 0.79 ALDH1A1 (0.41) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL3579460 0.79 KCNH2 (0.39) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL3088667 0.79 KCNH2 (0.39) CNR2ALDH1A1NPSR1ATMSMN1; SMN2
SCHEMBL3088332 0.79 NR1I2 (0.38) ALDH1A1NPSR1ATMSMN1; SMN2CYP3A4
SCHEMBL5440646 0.79 USP14 (0.44) USP14PTGDR2CNR2ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795247-B2 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-09-14 US disclosed
EP-1807403-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-07-18 EP disclosed
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) 2006-05-11 US disclosed
WO-2006046030-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents IDO1, ZC3HAV1, IDO2 USP14 2307/4885PTGDR 1444/4885PTGDR2 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.